We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+21.38%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$207M
AUM Growth
+$48.8M
Cap. Flow
+$32.1M
Cap. Flow %
15.53%
Top 10 Hldgs %
98.36%
Holding
16
New
2
Increased
3
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
PHAT icon
Phathom Pharmaceuticals
PHAT
+$30.2M
2
SLNO
Soleno Therapeutics
SLNO
+$3.92M
3
XCUR icon
Exicure
XCUR
+$1.98M
4
MTEM
Molecular Templates, Inc.
MTEM
+$1.92M
5
TARA icon
Protara Therapeutics
TARA
+$36.3K

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$5.96M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PSNL icon
1
Personalis
PSNL
$1.35B
$59.3M 28.65%
5,449,294
– –
PHAT icon
2
Phathom Pharmaceuticals
PHAT
$708M
$37.4M 18.09%
+1,203,135
New +$30.2M
CRSP icon
3
CRISPR Therapeutics
CRSP
$4.73B
$31.6M 15.28%
519,198
-109,200
-17% -$5.96M
SIEN
4
DELISTED
Sientra, Inc.
SIEN
$21.3M 10.31%
239,084
– –
SLNO
5
DELISTED
Soleno Therapeutics
SLNO
$19.9M 9.63%
464,618
+153,333
+49% +$3.92M
XCUR icon
6
Exicure
XCUR
$10.2M
$19.9M 9.61%
46,513
+4,846
+12% +$1.98M
VRNA
7
DELISTED
Verona Pharma
VRNA
$5.23M 2.53%
901,943
– –
PRTK
8
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$4.18M 2.02%
1,041,131
– –
MTEM
9
DELISTED
Molecular Templates, Inc.
MTEM
$2.8M 1.35%
+13,333
New +$1.92M
SYRE icon
10
Spyre Therapeutics
SYRE
$8.54B
$1.83M 0.89%
9,620
– –
CHMA
11
DELISTED
Chiasma, Inc. Common Stock
CHMA
$1.83M 0.89%
370,671
– –
TARA icon
12
Protara Therapeutics
TARA
$220M
$879K 0.42%
53,613
+3,166
+6% +$36.3K
OBSV
13
DELISTED
ObsEva SA Ordinary Shares
OBSV
$335K 0.16%
87,999
– –
CBAY
14
DELISTED
Cymabay Therapeutics
CBAY
$256K 0.12%
131,036
– –
SRRA
15
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$74K 0.04%
5,417
– –
OCGN icon
16
Ocugen
OCGN
$416M
$4K ﹤0.01%
7,111
– –

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q4 2019 Portfolio in Review

As of Q4 2019, Abingworth held 16 positions worth $207M, up 31% from $158M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Abingworth deployed $32.1M of net new capital in Q4 2019, opening 2 new positions and adding to 3 existing holdings. Its largest new stake was Phathom Pharmaceuticals: 1,203,135 shares worth $37.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was CRISPR Therapeutics, an estimated $5.96M trimmed.

  • Abingworth's largest Q4 2019 buy was Phathom Pharmaceuticals: 1,203,135 shares worth $37.4M.
  • Abingworth added most to Soleno Therapeutics in Q4 2019, an estimated $3.92M increase.
  • Abingworth's biggest Q4 2019 reduction was CRISPR Therapeutics, cutting an estimated $5.96M.
  • Abingworth's ten largest holdings make up 98% of its $207M portfolio in Q4 2019.
  • Abingworth opened 2 new positions and closed 0 in Q4 2019.
  • Abingworth's portfolio value rose 31% quarter-over-quarter to $207M.

Based on Abingworth's 13F filing for Q4 2019, filed 14 Feb 2020.